Long-term survival and patterns of care in women with ovarian tumors of low malignant potential

被引:129
作者
Trimble, CL
Kosary, C
Trimble, EL
机构
[1] NCI, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ Hosp, Dept Gynecol & Obstet, Baltimore, MD 21287 USA
关键词
D O I
10.1006/gyno.2002.6711
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The objectives of this study were to ascertain long-term survival and patterns of care among women diagnosed with ovarian tumors of low malignant potential (LMP) in a population-based data set. Methods. Using the NCI's Surveillance, Epidemiology, and End Results (SEER) database, we identified 2818 women diagnosed with ovarian tumors of low malignant potential between 1988 and 1997. Results. By FIGO stage, 10-year relative survival was as follows: stage I, 99%; stage II, 98%; stage 111, 96%; and stage IV 77%. One-quarter of women with stage I disease underwent partial or unilateral oophorectomy only, while women with more advanced disease commonly underwent omentectomy, unilateral or bilateral oophorectomy, and hysterectomy. Adjuvant chemotherapy was given to about 30% of women with stage III and IV disease. Radiation therapy was rarely used. We observed no significant changes in primary surgery or adjuvant treatment over time. Conclusions. The diagnosis of an ovarian tumor of LMP conveys a relatively benign prognosis. Conservative surgery should be considered in younger women with early-stage disease. There are insufficient data to support a role for adjuvant chemotherapy for women with advanced disease. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:34 / 37
页数:4
相关论文
共 20 条
[1]  
Bjorge T, 1998, INT J CANCER, V75, P663, DOI 10.1002/(SICI)1097-0215(19980302)75:5<663::AID-IJC1>3.3.CO
[2]  
2-4
[3]   Micropapillary serous carcinoma of the ovary - A distinctive low-grade carcinoma related to serous borderline tumors [J].
Burks, RT ;
Sherman, ME ;
Kurman, RJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (11) :1319-1330
[4]   Epithelial ovarian tumors of low malignant potential: The role of microinvasion [J].
Buttin, BM ;
Herzog, TJ ;
Powell, MA ;
Rader, JS ;
Mutch, DG .
OBSTETRICS AND GYNECOLOGY, 2002, 99 (01) :11-17
[5]  
Gershenson DM, 1998, CANCER, V83, P2157, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO
[6]  
2-D
[7]  
Gershenson DM, 1999, CLIN CANCER RES, V5, P4053
[8]  
Gershenson DM, 1998, CANCER, V82, P1096, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1096::AID-CNCR13>3.3.CO
[9]  
2-C
[10]   Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors [J].
Gotlieb, WH ;
Freidman, E ;
Bar-Sade, RB ;
Kruglikova, A ;
Hirsh-Yechezkel, G ;
Modan, B ;
Inbar, M ;
Davidson, B ;
Kopolovic, J ;
Novikov, I ;
Ben-Baruch, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (13) :995-1000